IL33 and lymphoma: Likewise, in EG7 lymphoma, B16, and inducible BrafV600EPTEN melanoma models exogenous IL-33 activated myeloid DCs within the tumor microenvironment increasing antigen cross-presentation and restoring anti-tumor T cell activity in a ST2, MyD88, and STAT1-dependent manner (50).